LifeArc and Action Medical Research launch funding call for research into rare diseases in children
£1m for translational research projects focussed on children’s rare diseases
Have you applied yet? Applications are open for LifeArc-@AUTM #technologytransfer #Fellowship. Apply by midnight (U… https://t.co/dwTGSRHR4w
LifeArc appoints new Chief Investment Officer (CIO)
Graham Duce appointed to the newly created role of CIO to ensure that we have a sustainable approach to income generation
Celebrating the successes of UK translation – our 2019 annual reception
Melanie Lee, LifeArc CEO acknowledges the success of the life sciences and translational research sectors in the UK
Patients with ultra-rare bone marrow disease set to benefit from £1.15m grant from LifeArc and The Aplastic Anaemia Trust
A research grant to investigate the potential of a novel type of “personalised cellular therapy” to reverse the ultra-rare condition, aplastic anaemia
LifeArc Seed Fund makes £1.5million investment in Caldan Therapeutics to develop novel treatments for metabolic diseases
Investment to allow Caldan to translate work on free fatty acid receptors initiated in their laboratories
Kymab and LifeArc enter strategic partnership to discover new medicines using Kymab’s IntelliSelect® technologies
The agreement will enable LifeArc to enhance our antibody drug discovery capabilities
LifeArc invests £1.5 million in Ducentis BioTherapeutics
LifeArc’s Seed Fund has invested £1.5 million in Ducentis BioTherapeutics to develop novel drug therapies for inflammatory and autoimmune disease
LifeArc monetises Keytruda® royalty interests to fund further research and investment
LifeArc receives US$1.3bn for a portion of royalty interests in Keytruda (pembrolizumab), making us one of the UK’s leading medical research charities by size of investment assets
Medicines Discovery Catapult and LifeArc launch strategic R&D partnership in biomarker discovery and proteomics technology
Three-year partnership to fund clinical application of biomarker strategies to help progress novel drug candidates to clinical evaluation stage